Suco de laranja probiótico contendo Pediococcus acidilactici CE51 modula a microbiota intestinal e atenua inflamação induzida em um modelo murino de colite

Abstract

The management of inflammatory bowel diseases has been widely investigated, especially ulcerative colitis. Thus, studies are needed with new probiotic products application in the prevention and/or treatment of these clinical situations. The aim of this study was to evaluate the effects of probiotic orange juice containing Pediococcus acidilactici CE51 in murine colitis model. 45 male Swiss lineage mice were used, divided into five groups (n = 9): control, colitis, colitis + probiotic (probiotic orange juice containing CE51), colitis+placebo (orange juice) and colitis+sulfasalazine (10mg / kg /Weight). Colitis induction was performed with dextran sulfate sodium (3%). The treatment time was 5 and 15 days after induction. Histopathological analyzes, serious measurements of TNF-alpha and C-reactive protein and metagenomic analysis of feces were performed after euthanasia. Probiotic treatment reduced inflammation in the small intestine, large intestine and spleen. The probiotic did not alter the serum levels of TNF-alpha and C-reactive protein, maintained the quantitative ratio of the phylum Firmicutes/Bacteroidetes and increased Lactobacillus helveticus with 5 and 15 days of treatment, respectively (p <0.05). The probiotic orange juice containing P. acidilactici CE51 modulated the intestinal microbiota and attenuated the inflammation induced in colitis.